coronavirus
cov
infect
human
mani
anim
speci
associ
respiratori
enter
hepat
central
nervou
system
diseas
larg
size
cov
genom
instabl
cov
replicas
gene
sequenc
propag
bacteria
repres
seriou
obstacl
develop
revers
genet
system
similar
use
smaller
posit
sens
rna
virus
overcom
limit
sever
altern
convent
plasmidbas
approach
establish
last
year
report
briefli
review
discuss
differ
revers
genet
system
develop
cov
pay
special
attent
sever
acut
respiratori
syndrom
cov
sarscov
coronavirus
cov
envelop
rna
virus
mainli
respons
respiratori
enter
infect
anim
human
lai
et
al
master
histor
cov
infect
human
associ
mild
upper
respiratori
tract
diseas
caus
human
cov
hcov
master
howev
identif
novel
lifethreaten
cov
caus
sever
acut
respiratori
syndrom
sarscov
redefin
histor
percept
stadler
et
al
recent
three
novel
hcov
associ
respiratori
diseas
identifi
includ
associ
chronic
pulmonari
diseas
woo
et
al
caus
upper
lower
respiratori
tract
diseas
children
adult
worldwid
van
der
hoek
et
al
recent
emerg
april
middl
east
respiratori
syndrom
cov
merscov
associ
acut
pneumonia
occasion
renal
failur
zaki
et
al
find
potenti
relev
cov
import
human
pathogen
highlight
need
revers
genet
system
facilit
genet
manipul
viral
genom
studi
fundament
viral
process
develop
vaccin
candid
test
antivir
drug
cov
belong
coronavirida
famili
within
order
nidoviral
de
groot
et
al
contain
largest
known
rna
genom
among
rna
virus
consist
plussens
cap
polyadenyl
rna
molecul
kb
length
first
twothird
genom
encod
replicas
gene
compris
two
overlap
open
read
frame
orf
orf
orf
latter
translat
ribosom
frameshift
mechan
translat
orf
result
synthesi
two
polyprotein
process
viral
proteinas
releas
replicationtranscript
complex
compon
final
onethird
genom
includ
gene
encod
structur
protein
e
n
well
genu
specif
protein
characterist
cov
express
nest
set
cotermin
subgenom
mrna
master
ziebuhr
recent
studi
cov
genet
broadli
restrict
analysi
temperaturesensit
ts
mutant
baric
lai
cavanagh
schaad
baric
stalcup
et
al
defect
rna
templat
depend
replicas
protein
provid
tran
helper
viru
izeta
et
al
narayanan
makino
repass
makino
william
et
al
recombin
virus
gener
target
recombin
master
master
rottier
revers
genet
system
devis
cov
time
clear
whether
construct
fulllength
infecti
cdna
clone
would
ever
technic
feasibl
target
rna
recombin
origin
develop
mous
hepat
viru
mhv
take
advantag
high
rate
homolog
rna
recombin
cov
baric
et
al
kuster
et
al
makino
et
al
system
synthet
donor
rna
expand
last
kb
genom
transfect
cell
infect
recipi
parent
viru
present
characterist
select
ts
phenotyp
host
rangebas
select
mutant
recombin
virus
identifi
counterselect
recipi
parent
viru
purifi
despit
valu
target
rna
recombin
present
clear
limit
inabl
easili
manipul
replicas
gene
studi
lethal
mutat
due
requir
viru
passag
therefor
develop
revers
genet
approach
base
fulllength
cdna
limit
provid
tremend
encourag
studi
cov
biolog
howev
larg
size
genom
around
kb
instabl
cov
replicas
gene
sequenc
propag
clone
cdna
bacteria
difficulti
synthes
fulllength
transcript
vitro
hamper
gener
cov
fulllength
infecti
cdna
clone
recent
problem
overcom
employ
three
creativ
nontradit
approach
base
use
bacteri
artifici
chromosom
bac
almazan
et
al
vitro
ligat
cdna
fragment
yount
et
al
vaccinia
viru
vector
propag
cov
fulllength
cdna
thiel
et
al
report
review
discuss
three
differ
approach
develop
build
cov
infecti
cdna
use
sarscov
model
cov
revers
genet
system
extend
gener
cov
replicon
rna
first
cov
fulllength
infecti
cdna
clone
gener
transmiss
gastroenter
viru
tgev
use
bac
approach
almazan
et
al
gonzalez
et
al
system
fulllength
cdna
copi
viral
genom
assembl
bac
plasmid
wang
et
al
synthet
lowcopynumb
plasmid
base
escherichia
coli
ffactor
shizuya
et
al
present
strictli
control
replic
lead
one
two
plasmid
copi
per
cell
plasmid
allow
stabl
mainten
bacteria
larg
dna
fragment
varieti
complex
genom
sourc
adler
et
al
shizuya
et
al
minim
toxic
associ
sever
cov
sequenc
amplifi
highcopynumb
plasmid
fulllength
cdna
assembl
control
cytomegaloviru
cmv
immediateearli
promot
allow
express
viral
rna
nucleu
cellular
rna
polymeras
ii
dubenski
et
al
flank
end
poli
tail
hepat
delta
viru
hdv
ribozym
bovin
growth
hormon
bgh
termin
polyadenyl
sequenc
produc
synthet
rna
bear
authent
end
viral
genom
dnalaunch
system
ensur
cap
viral
rna
allow
recoveri
infecti
viru
cdna
clone
without
need
vitro
transcript
step
use
approach
bac
clone
carri
infecti
genom
sarscov
urbani
strain
gener
three
step
fig
first
step
select
appropri
restrict
site
viral
genom
absent
bac
plasmid
case
adequ
restrict
site
avail
viral
genom
new
restrict
site
could
gener
introduct
silent
mutat
second
step
intermedi
bac
plasmid
pbacsarscov
gener
backbon
assembl
fulllength
cdna
clone
plasmid
contain
end
genom
control
cmv
promot
multiclon
site
contain
restrict
site
select
first
step
end
genom
follow
synthet
poli
hdv
ribozym
bgh
termin
polyadenyl
sequenc
final
fulllength
cdna
clone
pbacsarscov
fl
assembl
sequenti
clone
five
overlap
cdna
fragment
multiclon
site
intermedi
bac
plasmid
fig
overlap
cdna
fragment
flank
appropri
restrict
site
gener
standard
revers
transcript
pcr
rtpcr
assembl
sarscov
bac
clone
fulli
stabl
e
coli
infecti
viru
rescu
transfect
suscept
cell
bac
approach
present
sever
advantag
high
stabil
exogen
sequenc
unlimit
product
cdna
clone
high
effici
cdna
transfect
mammalian
cell
intracellular
express
viral
rna
furthermor
manipul
bac
clone
rel
easi
essenti
similar
convent
plasmid
slight
modif
owe
larg
size
bac
clone
presenc
plasmid
one
two
copi
per
cell
shizuya
et
al
besid
standard
protocol
manipul
convent
plasmid
bac
clone
could
easili
effici
modifi
e
coli
homolog
recombin
use
twostep
procedur
combin
red
recombin
system
counterselect
home
endonucleas
iscei
jamsai
et
al
lee
et
al
tischer
et
al
zhang
et
al
first
step
linear
marker
construct
contain
desir
modif
iscei
recognit
site
insert
via
red
recombin
target
site
use
posit
select
second
step
induc
iscei
cleav
recognit
site
creat
dna
doubl
strand
break
adjoin
duplic
sequenc
previous
introduc
use
substrat
second
intramolecular
red
recombin
result
loss
previous
introduc
marker
novel
approach
result
accur
highli
effici
method
introduc
insert
delet
point
mutat
bac
clone
without
retent
unwant
foreign
sequenc
addit
sarscov
tgev
bac
approach
success
use
engin
infecti
clone
stjean
et
al
felin
infecti
periton
viru
fipv
balint
et
al
recent
emerg
merscov
almazan
et
al
last
case
combin
synthet
biolog
use
bac
allow
gener
merscov
infecti
clone
four
month
first
merscov
outbreak
illustr
power
bac
approach
recent
modifi
bac
approach
use
gener
fulllength
cdna
clone
sarscov
strain
pfefferl
et
al
relat
clinic
isol
tylor
et
al
assembl
bac
control
rna
polymeras
promot
case
strain
infecti
viru
rescu
transfect
fulllength
transcript
deriv
vitro
transcript
linear
bac
construct
approach
combin
plasmidbas
handl
infecti
clone
direct
deliveri
genomelik
rna
cytoplasm
circumv
transcript
infecti
clone
nucleu
driven
cmv
promot
avoid
possibl
splice
howev
although
splice
could
occur
nuclear
express
viral
genom
effici
phenomenon
low
affect
recoveri
infecti
viru
almazan
et
al
contrast
case
isol
infecti
viru
recov
situ
cell
transfect
bac
clone
infect
modifi
vaccinia
ankara
express
rna
polymeras
system
vitro
transcript
step
also
avoid
revers
genet
approach
success
use
studi
role
specif
viral
protein
viral
replic
pathogenesi
gener
genet
attenu
virus
potenti
vaccin
candid
sarscov
cov
almazan
et
al
dediego
et
al
enjuan
et
al
fett
et
al
lamirand
et
al
netland
et
al
method
origin
appli
tgev
yount
et
al
involv
assembl
fulllength
cdna
panel
contigu
cdna
fragment
span
entir
viral
genom
flank
nativ
engin
specif
restrict
site
characterist
allow
systemat
precis
assembl
fulllength
cdna
vitro
ligat
assembl
fulllength
cdna
contain
rna
polymeras
promot
end
poli
tail
end
vitro
transcrib
gener
cap
fulllength
transcript
use
togeth
cap
n
gene
transcript
effici
recov
infecti
viru
transfect
suscept
cell
approach
fragment
boundari
arrang
way
interrupt
genom
region
unstabl
propag
clone
cdna
bacteria
follow
strategi
genomelength
cdna
sarscov
urbani
strain
gener
vitro
ligat
fig
yount
et
al
initi
panel
six
contigu
cdna
fragment
span
entir
sarscov
genom
gener
standard
rtpcr
use
specif
primer
introduc
uniqu
bgli
restrict
site
end
fragment
without
alter
amino
acid
code
sequenc
viru
bgli
class
ii
restrict
enzym
cleav
symmetr
palindrom
sequenc
leav
differ
asymmetr
overhang
randomli
selfassembl
anneal
complementari
overhang
gener
ident
bgli
site
cdna
fragment
systemat
unidirect
assembl
fulllength
cdna
vitro
ligat
vitro
transcript
genomelength
transcript
use
recov
infecti
viru
vitro
assembl
techniqu
combin
synthet
biolog
use
success
engin
infecti
clone
bat
sarslik
cov
becker
et
al
recent
identifi
merscov
scobey
et
al
one
potenti
problem
approach
sever
silent
mutat
insert
genom
avoid
potenti
transcript
termin
signal
introduc
uniqu
bgli
site
use
assembl
fulllength
cdna
clone
overcom
problem
variat
approach
use
engin
mhv
infecti
cdna
strategi
base
incorpor
type
ii
restrict
enzym
sapi
bsai
bsmi
among
other
end
cdna
fragment
enzym
recogn
asymmetr
site
cleav
extern
recognit
sequenc
leav
variabl
end
anneal
complementari
overhang
gener
ident
site
site
use
type
ii
restrict
enzym
site
two
contigu
cdna
fragment
could
ligat
vitro
tradit
clone
approach
leav
restrict
site
within
viral
genom
sequenc
howev
due
asymmetr
natur
recognit
site
simpl
revers
orient
allow
insert
site
end
two
adjac
cdna
fragment
variabl
overhang
gener
viru
sequenc
see
clone
strategi
upon
cleavag
ligat
restrict
site
remov
leav
exact
viral
sequenc
junction
approach
allow
gener
cdna
clone
without
mutat
viral
genom
sequenc
follow
modifi
approach
fulllength
cdna
clone
mhv
gener
either
sequenti
sever
step
simultan
vitro
ligat
seven
cdna
fragment
cover
entir
mhv
genom
feasibl
method
demonstr
later
success
assembl
fulllength
infecti
clone
infecti
bronchiti
viru
ibv
fang
et
al
tan
et
al
youn
et
al
revers
genet
system
inclus
n
transcript
transfect
process
shown
enhanc
viru
rescu
analyz
case
although
mechan
action
larg
unknown
vitro
cdna
assembl
approach
simpl
straightforward
allow
rapid
mutagenesi
independ
cdna
fragment
parallel
use
convent
techniqu
compat
bac
vaccinia
vector
furthermor
use
see
technolog
possibl
mutat
given
nucleotid
viral
genom
design
primer
incorpor
type
ii
restrict
site
mutat
interest
variabl
domain
recognit
site
ad
type
ii
restrict
site
proper
orient
site
remov
reassembl
leav
mutat
interest
final
dna
product
donaldson
et
al
yount
et
al
revers
genet
approach
success
use
studi
role
specif
viral
protein
sarscov
replic
pathogenesi
identifi
zoonot
vaccin
candid
strain
deme
et
al
develop
recombin
safe
vaccin
platform
use
novel
strategi
prevent
recombin
wildtyp
recombin
virus
rewir
viral
transcript
regul
sequenc
trss
altern
revers
genet
system
studi
biolog
pathogenesi
cov
base
clone
propag
cov
genom
cdna
vaccinia
viru
vector
eriksson
et
al
thiel
siddel
approach
first
describ
gener
recombin
thiel
et
al
subsequ
appli
success
engin
fulllength
infecti
clone
mhv
coley
et
al
sarscov
van
den
worm
et
al
ibv
casai
et
al
fipv
teke
et
al
teke
et
al
approach
present
advantag
clone
capac
poxviru
vector
vaccinia
viru
particular
exce
kb
foreign
sequenc
smith
moss
recombin
vaccinia
viru
genom
stabl
infecti
replic
effici
tissu
cultur
vaccinia
viru
vector
design
insert
foreign
dna
vitro
ligat
merchlinski
moss
develop
thu
obviat
need
plasmid
intermedi
contain
entir
cdna
insert
final
vaccinia
virusmedi
homolog
recombin
strategi
avail
make
access
site
direct
mutagenesi
cov
cdna
clone
vaccinia
vector
thiel
siddel
gener
revers
genet
system
sarscov
isol
van
den
worm
et
al
describ
illustr
vaccinia
virusbas
system
methodolog
revers
genet
system
divid
three
phase
fig
first
step
involv
gener
subgenom
cdna
fragment
prepar
larg
amount
either
amplif
bacteri
plasmid
dna
prepar
rtpcr
cdna
subsequ
ligat
vitro
produc
small
number
cdna
encompass
entir
genom
specif
ligat
strategi
determin
sequenc
particular
cov
mainli
consist
natur
occur
engin
restrict
site
sarscov
strain
five
cdna
fragment
encompass
whole
genom
initi
vitro
ligat
synthet
oligonucleotid
linker
result
gener
two
cdna
span
nucleotid
respect
van
den
worm
et
al
fig
crucial
step
process
modifi
cdna
contain
cov
genom
order
final
produc
infecti
rna
molecul
end
transcript
promot
sequenc
bacteriophag
rna
polymeras
locat
upstream
cov
genom
synthet
poli
end
genom
follow
uniqu
restrict
site
use
gener
runoff
transcript
fig
final
insert
cov
cdna
singl
noti
site
present
genom
dna
vaccinia
viru
vector
vnotitk
genom
termini
cdna
fragment
contain
restrict
site
eagi
lead
dna
end
compat
noticleav
vaccinia
viru
vector
dna
clone
step
sarscov
cdna
sequenc
problem
aros
instabl
bacteri
plasmid
viral
cdna
sequenc
nt
unexpect
rtpcr
introduc
mutat
delet
incorrect
cdna
region
replac
appropri
sarscov
sequenc
use
vaccinia
virusmedi
homolog
recombin
describ
second
step
vitro
assembl
cov
cdna
fragment
repres
fulllength
genom
cleav
eagi
ligat
vitro
long
short
arm
noticleav
vnotitk
vaccinia
viru
dna
merchlinski
moss
subsequ
ligat
reaction
transfect
mammalian
cell
infect
fowlpox
viru
helper
scheifling
et
al
rescu
recombin
vaccinia
virus
includ
cdna
cov
genom
sequenc
fowlpox
viru
infect
mammalian
cell
abort
possibl
recombin
event
poxvirus
extrem
rare
result
viru
stock
collect
cell
contain
exclus
recombin
vaccinia
virus
thiel
et
al
thiel
et
al
case
sarscov
two
recombin
vaccinia
virus
span
nucleotid
sarscov
sarscov
gener
fig
dna
deriv
vaccinia
virus
cleav
sfii
bgli
restrict
enzym
produc
compat
end
ligat
creat
cdna
contain
genomelength
sarscov
cdna
van
den
worm
et
al
final
recombin
cov
rescu
gener
genomiclength
rna
transcript
cov
cdna
insert
recombin
vaccinia
viru
purifi
recombin
vaccinia
viru
dna
contain
fulllength
cdna
cov
genom
cleav
uniqu
site
locat
downstream
poli
sequenc
repres
end
cov
genom
result
dna
use
templat
vitro
transcript
bacteriophag
rna
polymeras
gener
cap
rna
correspond
cov
genom
transcript
transfect
permiss
cell
lead
rescu
correspond
cov
tissu
cultur
supernat
limit
step
procedur
variabl
amount
puriti
fulllength
synthet
cov
rna
vitro
transcript
lead
sometim
failur
rescu
recombin
cov
therefor
altern
strategi
transcript
templat
dna
permiss
cell
express
bacteriophag
rna
polymeras
recombin
fowlpox
viru
britton
et
al
casai
et
al
previou
experi
vaccinia
viru
revers
genet
system
shown
n
transcript
may
becom
essenti
recu
cov
ibv
casai
et
al
therefor
contribut
posit
recoveri
cov
differ
method
involv
n
protein
express
use
initi
n
transcript
cotransfect
infecti
rna
describ
mhv
coley
et
al
recent
fulllength
sarscov
rna
synthes
vitro
rna
polymeras
transfect
bhk
cell
induc
express
sarscov
n
protein
chang
et
al
transfect
cell
cocultiv
suscept
cell
rescu
eventu
recombin
sarscov
van
den
worm
et
al
requir
n
protein
establish
product
cov
infect
infecti
rna
dna
shown
variabl
sever
cov
tgev
sarscov
merscov
effici
rescu
infecti
cdna
engin
bac
independ
n
protein
coexpress
almazan
et
al
almazan
et
al
similarli
rescu
vaccinia
viru
absenc
n
protein
express
tran
thiel
et
al
contrast
n
transcript
essenti
rescu
ibv
recombin
vaccinia
viru
casai
et
al
intermedi
situat
rescu
mhv
tgev
fulllength
cdna
construct
assembl
vitro
significantli
enhanc
inclus
ncode
transcript
baric
sim
yount
et
al
result
suggest
cov
cdna
engin
bac
transcrib
cellular
pol
ii
produc
infecti
rna
repres
effici
method
viru
recoveri
compar
system
reli
infecti
rna
transcrib
polymeras
sinc
revers
genet
system
depend
differ
extent
n
transcript
moment
clear
whether
n
transcript
n
protein
essenti
increas
viru
recoveri
yield
nevertheless
previou
result
shown
n
protein
involv
cov
rna
transcript
increas
rna
synthesi
almazan
et
al
schell
et
al
et
al
one
import
advantag
vaccinia
viru
revers
genet
system
vaccinia
virusmedi
homolog
recombin
ball
use
modifi
cov
genom
cdna
propag
vaccinia
viru
sitedirect
mutagenesi
strategi
extens
appli
introduc
heterolog
sequenc
genom
recombin
cov
van
den
worm
et
al
gene
delet
modif
lei
et
al
rothcross
et
al
stoke
et
al
even
repair
error
sequenc
coley
et
al
van
den
worm
et
al
two
recombin
method
base
sequenti
use
e
coli
guaninephosphoribosyl
transferas
gene
gpt
posit
neg
select
marker
armesto
et
al
britton
et
al
eriksson
et
al
develop
first
method
falkner
moss
thiel
siddel
cov
region
interest
recombin
vaccinia
viru
replac
e
coli
gpt
gene
gene
encod
plasmid
dna
flank
cov
sequenc
facilit
doubl
recombin
event
vaccinia
virus
contain
gpt
gene
expect
cov
genom
posit
isol
gptposit
select
mammalian
cell
second
step
introduc
gpt
gene
replac
gene
interest
encod
plasmid
dna
flank
cov
sequenc
mediat
doubl
homolog
recombin
event
isol
recombin
virus
gene
interest
requir
gptneg
select
cell
second
method
known
transient
domin
select
falkner
moss
kerr
smith
modifi
cov
cdna
region
insert
plasmid
contain
gpt
select
marker
control
vaccinia
viru
promot
complet
sequenc
plasmid
transient
integr
vaccinia
viru
includ
cov
genom
homolog
recombin
involv
singl
crossov
event
recombin
vaccinia
virus
express
gpt
gene
posit
select
final
gpt
marker
lost
absenc
select
pressur
singl
homolog
recombin
event
duplic
sequenc
two
recombin
event
occur
equal
frequenc
lead
either
gener
unmodifi
cov
sequenc
gener
cov
cdna
desir
modif
replicon
develop
sever
rna
virus
import
complementari
resourc
viru
revers
genet
system
bartenschlag
brass
et
al
frolov
et
al
khromykh
nakamura
et
al
zimmer
replicon
selfamplifi
nucleic
acid
contain
viral
protein
rna
signal
requir
viral
rna
synthesi
case
report
gene
facilit
analys
replicon
lack
structur
protein
infecti
viral
particl
produc
constitut
safe
altern
fulllength
infecti
cdna
especi
virus
moreov
stabl
cell
line
contain
noncytopath
select
viru
replicon
also
obtain
bartenschlag
therefor
replicon
repres
safe
tool
viru
replic
studi
antivir
compound
screen
even
setup
semiautom
highthroughput
screen
system
cov
replicon
gener
mani
cov
use
revers
genet
approach
describ
almazan
et
al
curti
et
al
ge
et
al
hertzig
et
al
thiel
et
al
replicon
use
identif
viral
cellular
factor
involv
cov
rna
synthesi
almazan
et
al
galan
et
al
moreno
et
al
antivir
drug
test
chen
et
al
case
sarscov
collect
replicon
engin
either
use
bac
system
vitro
ligat
ge
et
al
differ
replicon
version
includ
varieti
report
gene
green
fluoresc
protein
gfp
firefli
luciferas
fluc
renilla
luciferas
rluc
alon
combin
antibiot
select
gene
ahn
et
al
ge
et
al
pan
et
al
tanaka
et
al
genom
structur
rna
encod
cov
replicon
similar
case
contain
ci
act
signal
requir
viral
replic
larg
orf
encod
replicas
nonstructur
protein
nsp
n
gene
essenti
effici
cov
rna
synthesi
almazan
et
al
sarscov
replicon
obtain
vitro
ligat
also
includ
gfpblar
fusion
gene
locat
downstream
orf
transcript
control
gene
tr
trss
heterolog
report
gene
confer
resist
blasticidin
select
allow
gener
first
select
sarscov
replicon
cell
line
ge
et
al
sever
bacbas
sarscov
replicon
also
includ
heterolog
gene
locat
downstream
orf
rluc
express
control
trsn
tanaka
et
al
although
eventu
duplic
trsn
sequenc
could
lead
report
gene
loss
sever
replic
cycl
altern
flucneor
fusion
gene
confer
neomycin
resist
express
control
trsn
ahn
et
al
trsm
pan
et
al
case
antibiot
select
would
avoid
report
gene
loss
allow
futur
develop
select
cell
line
cov
replicon
could
also
deriv
replicationcompet
propagationdefect
virus
lack
e
gene
engin
tgev
curti
et
al
ortego
et
al
merscov
almazan
et
al
case
addit
safetyguard
must
introduc
work
contain
facil
line
sarscov
replicon
construct
base
attenu
sarscov
infecti
cdna
replac
structur
gene
gfp
report
gene
wang
et
al
replicon
use
antivir
drug
test
although
comprehens
evalu
replicon
safeti
perform
sarscov
replicon
use
analyz
molecular
basi
viral
rna
synthesi
viral
cellular
factor
involv
sens
function
nsp
sarscov
replic
analyz
avoid
use
infecti
viru
chen
et
al
tanaka
et
al
moreov
genomewid
analysi
viral
protein
involv
sarscov
rna
synthesi
pan
et
al
quantit
proteom
analysi
determin
host
cell
factor
involv
sarscov
replic
zhang
et
al
also
perform
use
replicon
date
despit
increas
effort
sinc
sarscov
outbreak
antivir
drug
approv
fda
exist
human
cov
barnard
kumaki
kilianski
baker
one
promis
applic
sarscov
replicon
use
antivir
drug
screen
sinc
sarscov
replicon
lack
structur
protein
compound
inhibit
viru
entri
morphogenesi
could
test
nevertheless
except
kilianski
baker
viru
life
cycl
step
poor
antivir
target
viru
escap
mutant
could
easili
recov
especi
viru
structur
protein
target
hand
replicas
protein
viral
rna
motif
involv
cov
replic
gener
conserv
mutat
rate
could
lower
structur
protein
due
higher
fit
pressur
fact
sever
key
enzymat
activ
main
proteas
papainlik
proteas
analyz
target
cov
antivir
drug
kilianski
baker
addit
sarscov
replicon
use
valid
antivir
compound
nucleic
acid
previous
identifi
use
vitro
screen
method
helicas
adedeji
et
al
frameshift
ahn
et
al
inhibitor
moreov
select
sarscov
replicon
cell
line
use
develop
semiautom
highthroughput
antivir
compound
screen
system
minimum
manipul
assay
setup
low
compound
volum
autom
detect
endpoint
fluoresc
ge
et
al
interestingli
screen
compound
librari
select
drug
test
good
correl
observ
fluoresc
level
sarscov
rna
protein
synthesi
highlight
system
suitabl
limit
kind
cellbas
screen
system
viral
cell
drug
target
identifi
analys
use
experiment
approach
requir
potenti
risk
public
health
pose
sarscov
cov
lack
specif
antivir
agent
vaccin
trigger
global
effort
studi
famili
virus
molecular
level
order
develop
effect
strategi
prevent
control
cov
infect
molecular
genet
analysi
structur
function
rna
viru
genom
profoundli
advanc
avail
fulllength
cdna
clone
case
cov
huge
genom
size
instabl
specif
cov
cdna
sequenc
bacteri
system
hinder
develop
infecti
cdna
clone
recent
tremend
amount
creativ
cov
field
result
develop
four
independ
uniqu
revers
genet
system
overcam
problem
revers
genet
system
establish
use
nontradit
approach
base
use
target
recombin
bac
vitro
ligat
cov
cdna
fragment
vaccinia
viru
vector
propag
cov
genom
cdna
avail
cov
fulllength
infecti
clone
recombin
virus
express
report
gene
constitut
import
tool
studi
cov
replic
transcript
mechan
virushost
interact
pathogenesi
also
rapid
ration
develop
test
genet
defin
vaccin
addit
fulllength
cdna
clone
gener
cov
replicon
greatli
facilit
function
analysi
viral
replic
transcript
well
analysi
antivir
drug
without
need
manipul
infecti
virus
